AstraZeneca India March Quarter Profit Jumps, Annual Profit Slips

AstraZeneca Pharma India reported a 47.5% year-on-year increase in net profit to ₹582.5 million for the January–March quarter, driven by strong revenue growth and higher other income. Quarterly revenue rose 25.4% to ₹4.8 billion, while net profit surged 88.8% sequentially.

Other income nearly doubled to ₹161.5 million, while total expenditure rose to ₹4.12 billion. The company incurred a one-time loss of ₹56.8 million, and tax expenses increased to ₹202.2 million.

For 2024–25, net profit fell 28.3% to ₹1.16 billion, despite a 32.5% rise in revenue to ₹17.16 billion. The board recommended a dividend of ₹32 per share.